サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1574933

疱疹状皮膚炎市場：薬剤クラス別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Dermatitis Herpetiformis Market, By Drug Class, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 311 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
疱疹状皮膚炎市場：薬剤クラス別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年10月02日
発行: AnalystView Market Insights
ページ情報: 英文 311 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

疱疹状皮膚炎の市場規模は、2023年に3億103万米ドルとなり、2024年から2032年にかけてCAGR7.29％で拡大しました。

治療には通常、厳格なグルテン除去食が含まれ、症状の軽減と将来の発症予防に役立ちます。また、かゆみや炎症を和らげるために薬物療法も行われます。罹患者の生活の質を向上させるためには、早期診断と適切な管理が重要です。

疱疹状皮膚炎市場 - 市場力学

グルテン過敏症とその皮膚症状に対する認識の高まりが需要を牽引

グルテン過敏症と疱疹状皮膚炎（DH）のような皮膚疾患との関連性に対する認識の高まりは、市場の主要促進要因です。グルテン不耐性の症状を認識する人が増えており、DHの検査や治療に対する需要が高まっています。米国国立衛生研究所（NIH）によると、米国では約141人に1人がDHと関連の深いセリアック病に罹患しているといいます。このような意識の高まりは、ヘルスケアプロバイダーと患者の双方に、より良い検査と管理の選択肢を求めることを促しています。その結果、製薬会社や医療機関は、この症状に対処するための具体的な治療法や教材の開拓に注力し、市場の成長を後押ししています。

疱疹状皮膚炎市場 - 主要洞察

リサーチアナリストの分析によると、世界市場は予測期間（2024年～2032年）においてCAGR約7.29%で年間成長すると推定されます。

薬剤クラス別では、ダプソンが2023年に最大の市場シェアを示すと予測されています。

投与経路別では、2023年には経口剤が主要タイプになりました。

エンドユーザー別では、2023年には病院が主要タイプとなりました。

地域別では、北米が2023年の売上高でトップとなりました。

疱疹状皮膚炎市場 - セグメンテーション分析：

世界の疱疹状皮膚炎市場は薬剤クラス別、投与経路別、エンドユーザー別、地域別に区分されます。

薬剤クラス別に3つのカテゴリーに分けられます：ダプソン、局所コルチコステロイド、抗ヒスタミン薬です。最も重要なのはダプソンです。ダプソンは抗生物質であり、この疾患に伴うかゆみや炎症を抑える効果があります。皮膚病変の消失に効果的に作用するため、多くの医師が好んで使用しています。即効性があり、症状を和らげることができるため、治療の選択肢の中でも際立っています。ダプソンの有効性は幅広い使用と推奨につながり、疱疹状皮膚炎市場におけるダプソンの存在感を高めています。

市場は投与経路によって2つのカテゴリーに分けられます：経口剤、局所剤、注射剤です。経口投与経路が最も重要かつ顕著です。これは、ダプソンをはじめとする経口治療薬が服用に便利で、症状の効果的な緩和をもたらすからです。経口治療は便利で非侵襲的であるため、患者さんは経口治療を好みます。注射薬や外用薬の選択肢もありますが、不快感や頻繁に塗布する必要があるなどの理由から、あまり好まれないです。全体として、内服薬は疱疹状皮膚炎を効果的に管理する上で重要な役割を果たしています。

疱疹状皮膚炎市場 - 地理的洞察

北米の疱疹状皮膚炎市場は、自己免疫疾患の多さと皮膚疾患に対する意識の高さから重要です。米国は先進的なヘルスケアシステムと強力な調査努力により、この市場をリードしています。

多くの臨床試験や承認に裏打ちされた、より革新的な治療や療法が利用できるようになってきています。カナダもまた、患者教育とサポートに注力することで、市場成長の一翼を担っています。この地域には多くの大手製薬企業が進出しており、共同研究や技術革新が盛んに行われています。

疱疹状皮膚炎市場 - 競合情勢：

疱疹状皮膚炎市場は競争が激しく、複数の主要企業が参入しています。GlaxoSmithKline、AbbVie、Novartisなどの大手企業は、自己免疫性皮膚疾患の治療法を開発しています。これらの企業は、既存の治療法を改善し、新たな治療法を生み出すために研究に投資しています。PfizerやJohnson & Johnsonのような企業も革新的な製品を市場に送り出しています。

さらに、Aclaris Therapeuticsのような中小企業は、ニッチ治療に特化することで成長を遂げています。全体として、疱疹状皮膚炎の管理を強化するための共同研究や技術革新に牽引され、状況はダイナミックです。

目次

第1章 疱疹状皮膚炎市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 疱疹状皮膚炎の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 疱疹状皮膚炎の産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 疱疹状皮膚炎市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 疱疹状皮膚炎の市場情勢

  • 疱疹状皮膚炎の市場シェア分析、2023年
  • 内訳データ：主要メーカー別
    • 既存企業の分析
    • 新興企業の分析

第7章 疱疹状皮膚炎市場：薬剤クラス別

  • 概要
    • セグメントシェア分析、薬剤クラス別
  • ダプソン
  • 局所コルチコステロイド
  • 抗ヒスタミン薬

第8章 疱疹状皮膚炎市場：投与経路別

  • 概要
    • セグメントシェア分析：投与経路別
    • 傾向
    • 局所
    • 注射剤

第9章 疱疹状皮膚炎市場：エンドユーザー別

  • 概要
    • セグメントシェア分析：エンドユーザー別
    • 病院
    • 皮膚科クリニック
    • 在宅医療
    • その他

第10章 疱疹状皮膚炎市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：疱疹状皮膚炎業界

  • 競合ダッシュボード
  • 企業プロファイル
    • GlaxoSmithKline
    • AbbVie
    • Amgen
    • Celgene（Bristol-Myers Squibb）
    • Novartis
    • Pfizer
    • Johnson & Johnson
    • Mylan
    • Takeda Pharmaceuticals
    • AstraZeneca
    • Regeneron Pharmaceuticals
    • Sanofi
    • Eli Lilly and Company
    • Dermira
    • Aclaris Therapeutics
    • Incyte Corporation
    • Teva Pharmaceutical Industries

第12章 アナリストの全方位展望

目次
Product Code: ANV3932

REPORT HIGHLIGHT

Dermatitis Herpetiformis Market size was valued at USD 301.03 Million in 2023, expanding at a CAGR of 7.29% from 2024 to 2032.

Dermatitis herpetiformis is a skin condition that causes itchy, blistering rashes. Dermatitis herpetiformis is linked to celiac disease, so it often occurs in people who cannot eat gluten, a protein found in wheat. When someone with celiac disease eats gluten, their body reacts by causing this skin rash. The rash usually appears on the elbows, knees, and buttocks but can show up anywhere on the body.

Treatment typically involves a strict gluten-free diet, which helps reduce symptoms and prevent future outbreaks. Medications can also be used to relieve itching and inflammation. Early diagnosis and proper management are important to improve the quality of life for those affected.

Dermatitis Herpetiformis Market- Market Dynamics

Growing awareness of gluten sensitivity and its skin manifestations drives demand.

The growing awareness of gluten sensitivity and its link to skin conditions like dermatitis herpetiformis (DH) is a key driver for the market. More people are recognizing the symptoms of gluten intolerance, which is increasing the demand for tests and treatments for DH. The National Institutes of Health (NIH) states that about 1 in 141 people in the U.S. has celiac disease, closely related to DH. This rising awareness encourages both healthcare providers and patients to seek better testing and management options. As a result, pharmaceutical companies and health organizations are focusing on developing specific treatments and educational materials to help address this condition, boosting market growth.

Dermatitis Herpetiformis Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.29% over the forecast period (2024-2032)

Based on Drug Class segmentation, Dapsone was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on End Users, Hospitals was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Dermatitis Herpetiformis Market- Segmentation Analysis:

The Global Dermatitis Herpetiformis Market is segmented based on Drug Class, Route of Administration, End User, and Region.

The market is divided into three categories based on Drug Class: Dapsone, Topical corticosteroids, and Antihistamines. Dapsone is the most significant. Dapsone is an antibiotic that helps reduce itching and inflammation associated with the condition. It works effectively to clear up skin lesions, making it a preferred choice for many doctors. Its quick action and ability to provide relief from symptoms make it stand out in the treatment options. Dapsone's effectiveness leads to its wide use and recommendation, driving its prominence in the dermatitis herpetiformis market.

The market is divided into two categories based on the Route of Administration: Oral, Topical, and Injectable. The oral route of administration is the most significant and prominent. This is because oral medications, like dapsone and other treatments, are convenient to take and offer effective relief from symptoms. Patients prefer oral treatments since they are convenient and non-invasive, making it simpler to manage the condition over time. Injectable and topical options are available, but they are less favored due to factors like discomfort or the need for more frequent applications. Overall, oral medications play a key role in managing dermatitis herpetiformis effectively.

Dermatitis Herpetiformis Market- Geographical Insights

The North American Dermatitis Herpetiformis market is important because of the high number of autoimmune diseases and greater awareness of skin conditions. The United States leads this market, thanks to its advanced healthcare system and strong research efforts.

More innovative treatments and therapies are becoming available, backed by many clinical trials and approvals. Canada also plays a role in market growth by focusing on patient education and support. With many major pharmaceutical companies in the region, there's a lot of collaboration and innovation.

Dermatitis Herpetiformis Market- Competitive Landscape:

The Dermatitis Herpetiformis market is competitive, with several key players involved. Major companies like GlaxoSmithKline, AbbVie, and Novartis develop treatments for autoimmune skin diseases. They invest in research to improve existing therapies and create new ones. Firms like Pfizer and Johnson & Johnson also contribute innovative products to the market.

Furthermore, smaller companies like Aclaris Therapeutics are seeing growth by specializing in niche treatments. Overall, the landscape is dynamic, driven by collaboration and innovation to enhance the management of Dermatitis herpetiformis.

Recent Developments:

In May 2023, AbbVie's aesthetics division expanded its product lineup with a recent FDA approval for a new product called Skinvive. This approval, granted this week, added to Allergan's Juvederm dermal filler range.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DERMATITIS HERPETIFORMIS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • GlaxoSmithKline
  • AbbVie
  • Amgen
  • Celgene (Bristol-Myers Squibb)
  • Novartis
  • Pfizer
  • Johnson & Johnson
  • Mylan
  • Takeda Pharmaceuticals
  • AstraZeneca
  • Regeneron Pharmaceuticals
  • Sanofi
  • Eli Lilly and Company
  • Dermira
  • Aclaris Therapeutics
  • Incyte Corporation
  • Teva Pharmaceutical Industries

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Dapsone
  • Topical corticosteroids
  • Antihistamines

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Topical
  • Injectable

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Dermatology Clinics
  • Homecare Settings
  • Others

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Dermatitis Herpetiformis Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Dermatitis Herpetiformis Market Snippet by Drugs Class
    • 2.1.2. Dermatitis Herpetiformis Market Snippet by Route of Administration
    • 2.1.3. Dermatitis Herpetiformis Market Snippet by End User
    • 2.1.4. Dermatitis Herpetiformis Market Snippet by Country
    • 2.1.5. Dermatitis Herpetiformis Market Snippet by Region
  • 2.2. Competitive Insights

3. Dermatitis Herpetiformis Key Market Trends

  • 3.1. Dermatitis Herpetiformis Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Dermatitis Herpetiformis Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Dermatitis Herpetiformis Market Opportunities
  • 3.4. Dermatitis Herpetiformis Market Future Trends

4. Dermatitis Herpetiformis Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Dermatitis Herpetiformis Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Dermatitis Herpetiformis Market Landscape

  • 6.1. Dermatitis Herpetiformis Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Dermatitis Herpetiformis Market - By Drugs Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drugs Class, 2023 & 2032 (%)
  • 7.2. Dapsone
  • 7.3. Topical corticosteroids
  • 7.4. Antihistamines

8. Dermatitis Herpetiformis Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Topical
    • 8.1.4. Injectable

9. Dermatitis Herpetiformis Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Dermatology Clinics
    • 9.1.4. Homecare Settings
    • 9.1.5. Others

10. Dermatitis Herpetiformis Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Dermatitis Herpetiformis Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Dermatitis Herpetiformis Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Dermatitis Herpetiformis Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Dermatitis Herpetiformis Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Dermatitis Herpetiformis Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Dermatitis Herpetiformis Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. GlaxoSmithKline
    • 11.2.2. AbbVie
    • 11.2.3. Amgen
    • 11.2.4. Celgene (Bristol-Myers Squibb)
    • 11.2.5. Novartis
    • 11.2.6. Pfizer
    • 11.2.7. Johnson & Johnson
    • 11.2.8. Mylan
    • 11.2.9. Takeda Pharmaceuticals
    • 11.2.10. AstraZeneca
    • 11.2.11. Regeneron Pharmaceuticals
    • 11.2.12. Sanofi
    • 11.2.13. Eli Lilly and Company
    • 11.2.14. Dermira
    • 11.2.15. Aclaris Therapeutics
    • 11.2.16. Incyte Corporation
    • 11.2.17. Teva Pharmaceutical Industries

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us